“It should be protocol that 100% of your patients with metastatic prostate cancer get germline testing. Full stop. No exceptions,” said Neal D. Shore, MD, FACS.
|Articles|January 16, 2010
- ONCOLOGY Vol 24 No 1_Suppl_1
- Volume 24
- Issue 1_Suppl_1
Risk Assessment in Stage II Colon Cancer
Author(s)Axel Grothey, MD
In this supplement to Oncology, guest editor Axel Grothey from the Mayo Clinic, explores adjuvant therapy considerations in stage II colon cancer from different angles.
Advertisement
Risk Assessment in Stage II Colon Cancer
This supplement and associated publication costs were funded by Genomic Health.
Over the past years, our understanding of stage II colon cancer has made significant advances leading to a refinement in the identification of the patient population and the treatment options considered appropriate as adjuvant therapy in this setting. In this supplement to Oncology, guest editor Axel Grothey from the Mayo Clinic, explores adjuvant therapy considerations in stage II colon cancer.
Articles in this issue
over 16 years ago
Risk Assessment in Stage II Colorectal Cancerover 16 years ago
Risk Assessment in Stage II Colon Cancer: To Treat or Not to Treatover 16 years ago
New Developments in the Adjuvant Therapy of Stage II Colon CancerAdvertisement
Related to this article
Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.
In the phase 3 NRG-CC009 trial, SRS led to longer overall survival vs HA-WBRT plus memantine with similar neurocognitive failure in SCLC brain metastases.
In a phase 1 first-in-human trial, BMS-986453 showed a favorable safety profile and high response rates in relapsed/refractory multiple myeloma.
Ayal Aizer, MD, MHS, discusses patients for whom single-fraction SRS may remain reasonable after brain metastasis resection.
Extended belantamab mafodotin dosing intervals were associated with maintained vision-related function in the phase 1 DREAMM-9 study.
The phase 3 NRG-GI003 trial showed no overall survival benefit with proton therapy over photon therapy in patients with advanced hepatocellular carcinoma.
In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA PET/CT–guided prostate biopsy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
2
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
3
Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care
4
Proton Therapy Does Not Improve Survival in Hepatocellular Carcinoma
5